ERBB2 and cancer: On the other hand, at the CNV level of all cancer-related genes, we found that ERBB2 (also known as HER2) amplified samples were more likely to have no peritoneal metastasis (q = 0.043, Supplementary Table S11), which might be a better treatment for HER2-amplified patients, such as HER2 inhibitors25.